Redeye provides a research update following the Q1 2024 report from Respiratorius. After market close yesterday, the company announced a rights issue amounting to cSEK28.6m in gross proceeds. The money is raised following positive signals regarding the patent situation in the US, and management views this as an opportunity to prolong the compay"s runway in the face of increased interest for VAL-001. We maintain our operational estimates, provide an overview of the sentiment in the biopharma deal landscape, and adjust our valuation to account for the capital raise.

Länk till analysen